Detalhe da pesquisa
1.
Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
Blood
; 132(24): 2546-2554, 2018 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30352784
2.
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.
Blood
; 131(8): 855-863, 2018 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29203585
3.
Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies.
Gynecol Oncol
; 156(2): 308-314, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31822399
4.
Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis.
Blood
; 130(9): 1132-1143, 2017 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-28630120
5.
A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma.
Am J Hematol
; 97(2): E54-E58, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34817872
6.
Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Eur J Cancer
; 190: 112950, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37441939
7.
p21-activated kinases as viable therapeutic targets for the treatment of high-risk Ewing sarcoma.
Oncogene
; 40(6): 1176-1190, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33414491
8.
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.
Leukemia
; 34(9): 2430-2440, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32094461
9.
Examination of behavioral deficits triggered by targeting Bdnf in fetal or postnatal brains of mice.
Neuroscience
; 142(1): 49-58, 2006 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-16844311